Concepedia

Shanzhi Gu

SG

Statistics

Publications

39

Citations

4K

H-Index

25

Active since

2005

Affiliations

Hunan Cancer Hospital(Current)

Sun Yat-sen University

Fudan University

Xi'an Jiaotong University

Zhongshan Hospital

Shanzhi Gu is an author at Hunan Cancer Hospital specializing in oncology, medicine, and pharmacology.

Publications per year

2005–2025

39

Publications

39

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Jianming Xu, Jie Shen, Shanzhi Gu et al. · Clinical Cancer Research · 2020 · 572 citations · Full text

Medicine, Oncology, Pharmacology +17

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin, Feng Bi, Shanzhi Gu et al. · Journal of Clinical Oncology · 2021 · 414 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang et al. · Signal Transduction and Targeted Therapy · 2023 · 283 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin, Li Qiu, Shanzhi Gu et al. · The Lancet. Gastroenterology & hepatology · 2021 · 254 citations

Medicine, Oncology, Pharmacotherapy +10

1–5 of 39